Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 65.75
-0.35 (-0.53%)
At close: Feb 6, 2026
SHA:603087 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,836 | 3,034 | 2,596 | 1,710 | 3,612 | 3,362 |
Other Revenue | 11.4 | 11.4 | 11.6 | 2.4 | 0.11 | - |
| 3,847 | 3,045 | 2,608 | 1,712 | 3,612 | 3,362 | |
Revenue Growth (YoY) | 30.54% | 16.77% | 52.31% | -52.60% | 7.44% | 16.13% |
Cost of Revenue | 949.65 | 777.15 | 724.7 | 443.93 | 399.9 | 309.82 |
Gross Profit | 2,898 | 2,268 | 1,883 | 1,268 | 3,212 | 3,052 |
Selling, General & Admin | 1,597 | 1,423 | 1,163 | 1,334 | 1,302 | 1,201 |
Research & Development | 545.46 | 541.05 | 501.02 | 562.47 | 474.59 | 419.99 |
Other Operating Expenses | 34.69 | 29.83 | 23.61 | 20.37 | 26.21 | 20.98 |
Operating Expenses | 2,159 | 1,974 | 1,703 | 1,944 | 1,822 | 1,637 |
Operating Income | 738.56 | 294.58 | 180.03 | -675.68 | 1,390 | 1,415 |
Interest Expense | -0.29 | -0.29 | -0.55 | -0.78 | -0.96 | - |
Interest & Investment Income | 111.5 | 153.46 | 141.01 | 186.63 | 321.99 | 67.38 |
Currency Exchange Gain (Loss) | 6.61 | 6.61 | 2.4 | -2.39 | -0.71 | 0.26 |
Other Non Operating Income (Expenses) | 53.68 | -2.03 | -0.8 | -1.6 | -3.34 | -3.83 |
EBT Excluding Unusual Items | 910.06 | 452.32 | 322.09 | -493.82 | 1,707 | 1,479 |
Gain (Loss) on Sale of Investments | 60.78 | 156.61 | -17.92 | -80.66 | -54.45 | -42.77 |
Gain (Loss) on Sale of Assets | 0.5 | 1.15 | -0.49 | -5.18 | -1.7 | -6.52 |
Asset Writedown | -4.16 | -5.02 | -12.55 | -40.92 | - | - |
Other Unusual Items | 25.32 | 25.32 | 15.01 | 38.1 | 44.96 | 16.12 |
Pretax Income | 992.49 | 630.39 | 306.14 | -582.47 | 1,696 | 1,445 |
Income Tax Expense | 66.75 | 15.72 | -34.09 | -142.96 | 243.26 | 214.76 |
Earnings From Continuing Operations | 925.74 | 614.66 | 340.23 | -439.52 | 1,453 | 1,231 |
Minority Interest in Earnings | - | 0 | -0.16 | 0 | 0 | 0 |
Net Income | 925.74 | 614.66 | 340.07 | -439.52 | 1,453 | 1,231 |
Net Income to Common | 925.74 | 614.66 | 340.07 | -439.52 | 1,453 | 1,231 |
Net Income Growth | 59.37% | 80.75% | - | - | 18.04% | 5.43% |
Shares Outstanding (Basic) | 588 | 591 | 567 | 563 | 561 | 533 |
Shares Outstanding (Diluted) | 588 | 591 | 567 | 563 | 561 | 533 |
Shares Change (YoY) | -0.16% | 4.28% | 0.58% | 0.46% | 5.28% | 5.43% |
EPS (Basic) | 1.57 | 1.04 | 0.60 | -0.78 | 2.59 | 2.31 |
EPS (Diluted) | 1.57 | 1.04 | 0.60 | -0.78 | 2.59 | 2.31 |
EPS Growth | 59.63% | 73.33% | - | - | 12.12% | - |
Free Cash Flow | -219.97 | 96.51 | -443.61 | -686.76 | 386.09 | 659.2 |
Free Cash Flow Per Share | -0.37 | 0.16 | -0.78 | -1.22 | 0.69 | 1.24 |
Dividend Per Share | 1.000 | 1.500 | 0.200 | - | 0.300 | 0.400 |
Dividend Growth | 42.86% | 650.00% | - | - | -25.00% | 12.01% |
Gross Margin | 75.32% | 74.48% | 72.21% | 74.07% | 88.93% | 90.78% |
Operating Margin | 19.20% | 9.67% | 6.90% | -39.46% | 38.49% | 42.08% |
Profit Margin | 24.06% | 20.18% | 13.04% | -25.67% | 40.22% | 36.61% |
Free Cash Flow Margin | -5.72% | 3.17% | -17.01% | -40.11% | 10.69% | 19.61% |
EBITDA | 1,012 | 545.57 | 400.79 | -479.87 | 1,571 | 1,574 |
EBITDA Margin | 26.31% | 17.91% | 15.37% | -28.03% | 43.49% | 46.83% |
D&A For EBITDA | 273.68 | 251 | 220.75 | 195.81 | 180.64 | 159.6 |
EBIT | 738.56 | 294.58 | 180.03 | -675.68 | 1,390 | 1,415 |
EBIT Margin | 19.20% | 9.67% | 6.90% | -39.46% | 38.49% | 42.08% |
Effective Tax Rate | 6.73% | 2.49% | - | - | 14.34% | 14.86% |
Revenue as Reported | 3,847 | 3,045 | 2,608 | 1,712 | 3,612 | 3,362 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.